Immunohistochemistry analyses demonstrated a significant presence of IDO2 in NSCLC [40], medullary thyroid carcinoma [42], B and T cell lymphomas [50], ovarian cell carcinoma [51], and glioblastoma [52]. Here, IDO2 is linked to non-small cell lung carcinoma.